For Research Use Only

HER2/ErbB2 Monoclonal antibody

Catalog Number:60311-1-lg 6 Publications



Basic Information	Catalog Number: 60311-1-lg	GenBank Accession Number: BC 156755	Purification Method: Protein A purification
	Size:	GenelD (NCBI):	CloneNo.:
	150ul , Concentration: 1500 ug/ml by		1B12A7
	Nanodrop;	UNIPROT ID:	Recommended Dilutions:
	Source:	P04626	IHC 1:800-1:3200
	Mouse	Full Name:	IF-P 1:50-1:500
	lsotype:	v-erb-b2 erythroblastic leukemia	
	lgG2b	viral oncogene homolog 2, neuro/glioblastoma derived	
	Immunogen Catalog Number: AG16463	oncogene homolog (avian)	
		Calculated MW: 1255 aa, 138 kDa	
Applications	Tested Applications:	Positive Co	ontrols:
	IHC, IF-P, ELISA IHC : human		n breast cancer tissue,
	Cited Applications: IHC, IF	IF-P : human breast cancer tissue,	
	Species Specificity: human		
	Cited Species: human		
	Note-IHC: suggested antigen r	etrieval with	
	TE buffer pH 9.0; (*) Alternativ retrieval may be performed w buffer pH 6.0		
Background Information	retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pu	ith citrate nsmembrane glycoprotein membe inases. It has no ligand-binding do to other ligand-bound EGF receptor cing kinase-mediated activation of otein kinase and phosphatidylinos ported in numerous cancers, includ	itol-3 kinase. Amplification and/or ing breast and ovarian tumors. HER2 is a
	retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pr overexpression of HER2 have been re therapeutic target for the treatment o	ith citrate nsmembrane glycoprotein membe inases. It has no ligand-binding do to other ligand-bound EGF receptor cing kinase-mediated activation of otein kinase and phosphatidylinos ported in numerous cancers, includ	main and therefore cannot bind growth family members to form a heterodimer, downstream signalling pathways, such a itol-3 kinase. Amplification and/or ing breast and ovarian tumors. HER2 is a
	retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pu overexpression of HER2 have been re therapeutic target for the treatment of Author Pub	ith citrate nsmembrane glycoprotein membe inases. It has no ligand-binding do to other ligand-bound EGF receptor cing kinase-mediated activation of otein kinase and phosphatidylinos ported in numerous cancers, includ f breast cancer and other carcinoma	main and therefore cannot bind growth family members to form a heterodimer, downstream signalling pathways, such a itol-3 kinase. Amplification and/or ing breast and ovarian tumors. HER2 is a is.
Background Information	retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pr overexpression of HER2 have been re therapeutic target for the treatment of Author Pub Yanlin Wu 301	ith citrate nsmembrane glycoprotein membe inases. It has no ligand-binding do to other ligand-bound EGF receptor cing kinase-mediated activation of otein kinase and phosphatidylinos ported in numerous cancers, includ f breast cancer and other carcinoma med ID Journal	main and therefore cannot bind growth family members to form a heterodimer, downstream signalling pathways, such a itol-3 kinase. Amplification and/or ing breast and ovarian tumors. HER2 is a as. Application
	retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pi overexpression of HER2 have been re therapeutic target for the treatment of Author Pub Yanlin Wu 301 Fei Xing 366	ith citrate nsmembrane glycoprotein membe inases. It has no ligand-binding doi to other ligand-bound EGF receptor cing kinase-mediated activation of otein kinase and phosphatidylinos ported in numerous cancers, includ f breast cancer and other carcinoma med ID Journal 27983 Oncol Lett	main and therefore cannot bind growth family members to form a heterodimer, downstream signalling pathways, such a itol-3 kinase. Amplification and/or ing breast and ovarian tumors. HER2 is a is. Application IHC
Notable Publications	retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan- those involving mitogen-activated pi overexpression of HER2 have been re therapeutic target for the treatment of Author Pub Yanlin Wu 301 Fei Xing 366	ith citrate nsmembrane glycoprotein membe inases. It has no ligand-binding do to other ligand-bound EGF receptor cing kinase-mediated activation of otein kinase and phosphatidylinos ported in numerous cancers, includ f breast cancer and other carcinoma med ID Journal 27983 Oncol Lett 27608 Mol Cancer	main and therefore cannot bind growth family members to form a heterodimer, downstream signalling pathways, such a itol-3 kinase. Amplification and/or ing breast and ovarian tumors. HER2 is a is. Application IHC IF
Notable Publications	retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pu overexpression of HER2 have been re therapeutic target for the treatment of Author Pub Yanlin Wu 301 Fei Xing 366 Xin Zhou 321 Storage: Store at -20°C. Stable for one year afte Storage Buffer:	ith citrate Insmembrane glycoprotein member inases. It has no ligand-binding doi to other ligand-bound EGF receptor cing kinase-mediated activation of otein kinase and phosphatidylinos ported in numerous cancers, includ f breast cancer and other carcinoma med ID Journal 27983 Oncol Lett 27608 Mol Cancer 27954 J Cancer er shipment.	main and therefore cannot bind growth family members to form a heterodimer, downstream signalling pathways, such a itol-3 kinase. Amplification and/or ing breast and ovarian tumors. HER2 is a is. Application IHC IF
	retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pr overexpression of HER2 have been re therapeutic target for the treatment of Author Pub Yanlin Wu 301 Fei Xing 366 Xin Zhou 321 Storage: Store at -20°C. Stable for one year after	ith citrate Insmembrane glycoprotein member Inases. It has no ligand-binding doi to other ligand-bound EGF receptor cing kinase-mediated activation of otein kinase and phosphatidylinos ported in numerous cancers, includ f breast cancer and other carcinome med ID Journal 27983 Oncol Lett 27608 Mol Cancer 27954 J Cancer er shipment. % glycerol, pH7.3	main and therefore cannot bind growth family members to form a heterodimer, downstream signalling pathways, such a itol-3 kinase. Amplification and/or ing breast and ovarian tumors. HER2 is a is. Application IHC IF


T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free E: proteintech@ptglab.com

in USA), or 1(312) 455-8498 (outside USA)

W: ptglab.com

Group brand and is not available to purchase from any other manufacturer.


Selected Validation Data




1x10^6 SK-BR-3 cells were surface stained with 0.2 µg HER2/ErbB2 Monoclonal antibody (60311-1-Ig, Clone: 1B12A7) and Coralite® Plus 647-Goat Anti-Mouse Recombinant Secondary Antibody (H+L) (Cat.NO.RGAM005). Mouse IgG2b isotype control (66360-3-Ig, Clone: 11B8C4) was parallel stained as control. Cells were not fixed.




Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 60311-1-Ig (HER2/ErbB2 antibody) at dilution of 1:1600 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 60311-1-Ig (HER2/ErbB2 antibody) at dilution of 1:1600 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (4% PFA) fixed human breast cancer tissue using 60311-1-lg (HER2/ErbB2 antibody), at dilution of 1:200 and CoraLite® 488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L).



Immunofluorescent analysis of (4% PFA) fixed human breast cancer tissue using 60311-1-Ig (HER2/ErbB2 antibody), at dilution of 1:200 and CoraLite@488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L).



Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 60311-1-Ig (HER2/ErbB2 antibody) at dilution of 1:40000 (under 10x Lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).